Home > Resources > Company Profiles > Affymetrix, Incorporated

Affymetrix, Incorporated (AFFX)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Enter the text you see in the image *

Letters are not case-sensitive, disregard spaces.

Try a New One

This helps us prevent automated registrations and spamming.

Email Confirmation

John C. Batty , CFO/Executive VP

www.affymetrix.com

Industry: Technology

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

The Company is engaged in the development, manufacture, sale & service of consumables & systems for genetic analysis in the life sciences & clinical healthcare markets and create tools that advances the understanding of the molecular basis of life.

Portfolio Articles

Gene-Sequencing Warrior
Illumina C.E.O. Jay Flatley is moving fast to outmaneuver rivals in a futuristic industry that stands to make billions of dollars off your DNA.
Feb 13 2008
Welcome to the Future
With a little help from Google, secretive Silicon Calley startup 23andMe is betting you’ll want to web-surf your own DNA. But is the science ready?

Oct 15 2007

See more news on this company

Portfolio Blogs

When's a Gene Test Not a Gene Test?
Jun 25 2008

Press Releases

Affymetrix and Asuragen Sign Agreement to Develop IVT Reagent Kits for Molecular Diagnostic Applications Jul-08-2008, 08:00AM EDT
Affymetrix Technology Used to Discover Molecular Mechanisms of Liver Disease Jun-30-2008, 08:00AM EDT
Center for Inherited Disease Research Adds Affymetrix Platform for Large-Scale Genotyping Services Jun-16-2008, 08:00AM EDT
Case Western Reserve University and TGen Select Affymetrix SNP Array 6.0 for Diabetes Study Jun-09-2008, 08:00AM EDT
Affymetrix Technology Powers First Genomic Tumor Grading Test for Breast Cancer May-30-2008, 08:00AM EDT

News From Around the Web

News

More Than Momentum: Stocks Rising for a Reason (Motley Fool)

Jul 08 2008
Affymetrix Reaches Agreement With Asuragen to Develop IVT Reagent Kits for Molecular Diagnostic Applications (RTTNews)

Jul 08 2008
Affymetrix and Asuragen Sign Agreement to Develop IVT Reagent Kits for Molecular Diagnostic Applications (PharmaLive)

Jul 08 2008
Designer diet for prostate cancer (First Science)

Jul 07 2008
Affymetrix Technology Used to Discover Molecular Mechanisms of Liver Disease (Genetic Engineering News)

Jun 30 2008
Genetic-Testing Company Details Regulatory Defense Plan (Wired)

Jun 24 2008
Exclusive: DNA Tester Reveals Cease-and-Desist Letter (Wired)

Jun 18 2008

Employees

Number of Employees: 1,141

Revenue per Employee: $326,167

Top Executives

James R. Gibson, II, Chief Accounting Officer/Controller/Vice President, Divisional

Barbara A. Caulfield, Esq., Secretary

Kevin M. King, President

Board of Directors

Vernon R. Loucks, Jr., Director

Dr. John D. Diekman, Ph.D., Director

John A. Young, Director

Robert P. Wayman, Director

Dr.Susan D. Desmond-Hellmann, M.D., M.P.H., Director

Dr.Stephen P.A. Fodor, Ph.D., Founder/CEO/Chairman of the Board/Director

Dr. Paul A. Berg, Ph.D., Director

Dr. Robert H. Trice, Ph.D., Director

David B. Singer, Director

Financials

Quarterly

Annual

Income Statement	04/2008	02/2008	10/2007	07/2007
Sales	31.66 Mil.	37.94 Mil.	27.3 Mil.	28.68 Mil.
Gross Operating Profit	137.92 Mil.	69.65 Mil.	67.68 Mil.	59.63 Mil.
Operating Income before D & A (EBITDA)	94.42 Mil.	16.37 Mil.	17.89 Mil.	6.56 Mil.
Total Income Before Interest Expenses (EBIT)	86.58 Mil.	20.99 Mil.	4.16 Mil.	2.24 Mil.
Total Net Income	46.25 Mil.	12.78 Mil.	2.58 Mil.	1.24 Mil.
Basic EPS, Total	0.68	0.19	0.04	0.02
Diluted EPS, Total	0.58	0.17	0.04	0.02

BALANCE STATEMENT	04/2008	02/2008	10/2007	07/2007
Cash and Equivalents	NA	288.64 Mil.	123.74 Mil.	91.14 Mil.
Total Assets	NA	667.11 Mil.	400.23 Mil.	394.73 Mil.
Total Liabilities	NA	84.04 Mil.	79.46 Mil.	85.65 Mil.
Total Capitalization	NA	1.03 Bil.	694.06 Mil.	688.04 Mil.

Cash Flow	04/2008	02/2008	10/2007	07/2007
Net Cash From Continuing Operations	NA	NA	19.36 Mil.	-4.56 Mil.
Net Cash From Investing Activities	NA	NA	-27.21 Mil.	-34.75 Mil.
Net Cash From Financing Activities	NA	NA	12.23 Mil.	11.32 Mil.
Net Change in Cash & Cash Equivalents	NA	NA	4.67 Mil.	-27.92 Mil.

Income Statement	2008	2007	2006	2005
Sales	138.72 Mil.	97.18 Mil.	73.63 Mil.	69.6 Mil.
Gross Operating Profit	232.6 Mil.	258.14 Mil.	293.97 Mil.	276.37 Mil.
Operating Income before D & A (EBITDA)	21.38 Mil.	26.72 Mil.	93.51 Mil.	85.07 Mil.
Total Income Before Interest Expenses (EBIT)	21.5 Mil.	-4.47 Mil.	64.15 Mil.	62.04 Mil.
Total Net Income	12.59 Mil.	-13.7 Mil.	57.52 Mil.	47.61 Mil.
Basic EPS, Total	0.18	-0.2	0.9	0.79
Diluted EPS, Total	0.17	-0.2	0.84	0.74

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	288.64 Mil.	119.06 Mil.	100.24 Mil.	42.6 Mil.
Total Assets	667.11 Mil.	383.89 Mil.	452.76 Mil.	322.95 Mil.
Total Liabilities	84.04 Mil.	93.59 Mil.	107.2 Mil.	96.74 Mil.
Total Capitalization	1.03 Bil.	672.96 Mil.	639.84 Mil.	369.19 Mil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	31.26 Mil.	64.61 Mil.	48.93 Mil.
Net Cash From Investing Activities	NA	-22.35 Mil.	-82.3 Mil.	-46.78 Mil.
Net Cash From Financing Activities	NA	9.76 Mil.	74.85 Mil.	-235.08 Mil.
Net Change in Cash & Cash Equivalents	NA	18.83 Mil.	57.64 Mil.	-233.33 Mil.

Affymetrix, Incorporated (AFFX)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request